Podcast
Author(s):
Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Sanofi, we passed the mic to Joseph Mikhael, MD, a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute and chief medical officer of the International Myeloma Foundation. Dr Mikhael moderated an OncLive® Insights workshop discussion on addressing disparities and practicing multicultural care in myeloma.
Dr Mikhael was joined by Craig Cole, MD, an assistant professor in the Division of Hematology and Oncology in the Department of Medicine in the College of Human Medicine at Michigan State University in East Lansing. Dr Cole is also a clinician at Karmanos Cancer Institute at McLaren Greater Lansing in Lansing, Michigan.
In this exclusive conversation, Drs Mikhael and Cole discussed ways to help reduce disparities in myeloma by delivering culturally relevant care. In particular, they highlighted the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are culturally and socially.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512